NCT04440943 - A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions

Non-small Cell Lung CancerBreast CancerGastric CancerRenal Cell CarcinomaOvarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerCholangiocarcinomaBladder Urothelial CarcinomaMSI-H Colorectal CancerEsophageal CancerHepatic CancerHead and Neck CancerOther Solid Tumors

Interventions

DRUG

CDX-527

CDX-527 is administered by infusion every 2 weeks

Trial Locations (5)

27710

Duke Cancer Center, Durham

30342

Northside Hospital, Atlanta

60637

University of Chicago, Chicago

68130

Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha

97213

Providence Portland Medical Center, Portland